Try a new search

Format these results:

Searched for:

person:carpet01

in-biosketch:true

Total Results:

40


PROSTATE FIDUCIAL MARKER PLACEMENT IN PATIENTS WHILE ON ANTICOAGULATION: FEASIBILITY PRIOR TO PROSTATE SBRT [Meeting Abstract]

Haas, Jonathan; Katz, Aaron; Harris, Joshua; Carpenter, Todd; Carbone, Susan; Kole, Thomas; Pristupa, Steven; Witten, Matthew; Blacksburg, Seth
ISI:000398276600099
ISSN: 0022-5347
CID: 3502622

Radiographic extracapsular extension and treatment outcomes in locally advanced oropharyngeal carcinoma

Kann, Benjamin H; Buckstein, Michael; Carpenter, Todd J; Bakst, Richard; Misiukiewicz, Krzysztof; Genden, Eric; Posner, Marshall; Kostakoglu, Lale; Som, Peter; Gupta, Vishal
BACKGROUND:Pathologic extracapsular extension (pECE) in metastatic lymph nodes is associated with poor prognosis for oropharyngeal carcinoma. The prognostic value of radiographic extracapsular extension (rECE) has not been studied. METHODS:A retrospective analysis was conducted of 111 patients with locally advanced oropharyngeal carcinoma treated in the Mount Sinai Radiation Oncology Department with accessible pretreatment CT reports. Univariate Kaplan-Meier and multivariate Cox regression analyses compared cohorts for locoregional control, distant control, progression-free (PFS), and overall survival (OS). RESULTS:Sixty-four patients had rECE-present and 47 had rECE-absent scans. The patients with rECE presence had significantly worse OS (3-year: 95% vs 77%; p = .006), PFS (3-year: 91% vs 71%; p = .002), and distant control (3-year: 98% vs 81%; p = .008), with no difference in locoregional control. On multivariate analysis, rECE-presence was a negative prognosticator for OS, PFS, and distant control. CONCLUSION/CONCLUSIONS:This study suggests that rECE is an independent prognosticator of poor distant control and survival with little impact on locoregional control for oropharyngeal carcinoma.
PMID: 24123603
ISSN: 1097-0347
CID: 3498442

Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck

Carpenter, Todd J; Kann, Benjamin; Buckstein, Michael H; Ko, Eric C; Bakst, Richard L; Misiukiewicz, Krzysztof J; Posner, Marshall R; Genden, Eric M; Gupta, Vishal
OBJECTIVES/OBJECTIVE:Overall treatment package time (from surgery to radiotherapy [RT] completion) > 100 days can portend poor outcomes in head and neck cancer. Faster postoperative recovery seen with transoral robotic surgery may decrease treatment duration and toxicity for adjuvant RT and chemoradiation. METHODS:We retrospectively reviewed all patients treated with transoral robotic surgery (n = 124) and adjuvant RT and chemoradiation (n = 33) at our institution for head and neck cancer from April 2007 to December 2011 to determine treatment duration, acute toxicity, and long-term percutaneous gastric tube rates. RESULTS:The median overall treatment time was 86 days and from surgery to RT start was 41 days; median RT duration was 44 days. No wound breakdown or infection occurred during or after RT. Two-year actuarial locoregional control, distant metastasis-free survival, and overall survival rates were 93%, 96%, and 97%, respectively. CONCLUSIONS:Adjuvant RT after transoral robotic surgery for head and neck cancer can be completed safely and in a timely fashion. Longer follow-up and a larger cohort will be needed to determine if this regimen is more effective than traditional surgery followed by adjuvant RT.
PMID: 24847162
ISSN: 0003-4894
CID: 3498452

Vocal cord paralysis after stereotactic body radiation therapy to the left lung apex [Case Report]

Carpenter, Todd J; Rosenzweig, Kenneth E
PMID: 25436809
ISSN: 1556-1380
CID: 3498472

Does response to induction chemotherapy (IC) predict locoregional control after concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LAHNC)? [Letter]

Cotter, Ryan; Blacksburg, Seth; Carpenter, Todd; Kann, Benjamin; Bakst, Richard; Misiukiewicz, Krzysztof; Posner, Marshall; Som, Peter; Gupta, Vishal
PMID: 24680084
ISSN: 1879-0593
CID: 3498002

Radiographic extracapsular extension (ECE) and treatment outcomes in locally advanced oropharyngeal carcinoma (OPC) [Meeting Abstract]

Kann, Benjamin H.; Buckstein, Michael; Carpenter, Todd J.; Golchin, Ava; Bakst, Richard Lorne; Misiukiewicz, Krzysztof; Genden, Eric Michael; Posner, Marshall R.; Kostakoglu, Lale; Som, Peter M.; Gupta, Vishal
ISI:000335419602143
ISSN: 0732-183x
CID: 3495622

Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up

Buckstein, Michael; Carpenter, Todd J; Stone, Nelson N; Stock, Richard G
OBJECTIVE:To report the outcomes and late toxicities in younger patients with long-term follow-up treated with brachytherapy with or without external beam radiotherapy for prostate adenocarcinoma. MATERIALS AND METHODS/METHODS:Patients treated with brachytherapy with or without external beam radiotherapy who were aged ≤ 60 years at treatment with ≥ 10 years of follow-up were selected from our database. The outcomes were analyzed regarding biochemical failure, distant metastases, and cause of death. Genitourinary outcomes were assessed using the International Prostate Symptom Score, Radiation Therapy Oncology Group, and Common Terminology Criteria for Adverse Events criteria. Gastrointestinal toxicity was measured using Radiation Therapy Oncology Group scales. Erectile dysfunction was measured using Sexual Health Inventory for Men and the Mount Sinai Erectile Function score. RESULTS:A total of 131 patients met the inclusion criteria, with a median age of 57 years at treatment and a median follow-up of 11.5 years. Of the patients in this cohort, 9.9% developed biochemical failure with 1 failure and 1 prostate cancer-related death after 10 years. The International Prostate Symptom Score were statistically unchanged after 10 years. Of 22 cases (17%) of grade 2 or greater genitourinary toxicities, only 6 (4.5%) continued after 10 years. Of 11 cases (8.3%) of grade 2 or greater gastrointestinal events, none persisted past 10 years. A significant decrease occurred in the mean Sexual Health Inventory for Men score from 19.5 to 15.3 (P = .008). Of the potent patients before treatment, 69% remained potent at last follow-up. A total of 4 second malignancies were detected, 2 of which were within the radiation field. CONCLUSION/CONCLUSIONS:Men <60 years old who underwent brachytherapy for prostate cancer can expect minimal late genitourinary and gastrointestinal toxicity after 10 years and excellent potency preservation.
PMID: 23374803
ISSN: 1527-9995
CID: 3498432

Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy

Carpenter, Todd J; Forsythe, Kevin; Kao, Johnny; Stone, Nelson N; Stock, Richard G
PURPOSE/OBJECTIVE:To evaluate the efficacy of multimodality therapy consisting of hormone therapy (HT), brachytherapy (BT), and external beam radiotherapy (EBRT) in extraprostatic prostate cancer and identify factors with predictive value. METHODS AND MATERIALS/METHODS:Between June 1992 and October 2006, 97 patients with extraprostatic prostate cancer received permanent seed implant BT. Extraprostatic disease was defined by one or more of the following: positive seminal vesicle biopsy (n=56), positive lymph node dissection (n=8), or a clinical tumor stage of T3 (n=48). Treatment consisted of BT alone with (103)Pd or (125)I (n=4); HT and BT (n=3); BT and EBRT (n=2); or trimodality therapy with HT, BT, and EBRT (n=88). Median followup was 69 (range, 23-182) months. Freedom from biochemical failure (FBF) rates were calculated using the Phoenix criteria. RESULTS:The 7-year actuarial FBF, freedom from distant metastases, disease-specific survival, and overall survival rates were 67%, 82%, 96%, and 81%, respectively. Biologically effective dose (BED) was the only variable significantly impacting FBF rates. FBF at 7 years was 60% vs. 74% for BED below 200 and 200 or above, respectively (p=0.048). Trends toward worse outcomes were noted with increasing Gleason score, with 7-year FBF rates of 86% vs. 71% vs. 55% for scores of 6 or less, 7, and 8-10, respectively (p=0.090). BED was the only significant predictor of FBF in multivariate analysis (p=0.032). None of the predictors were significant in multivariable analyses for the other outcomes studied. CONCLUSIONS:Trimodality approach achieves durable biochemical control in most patients with historically poor prognosis T3 prostate cancer. BED above 200Gy was associated with superior FBF.
PMID: 21106445
ISSN: 1873-1449
CID: 3498402

Novel approaches in conventional mechanical ventilation for paediatric acute lung injury

Carpenter, Todd
Acute lung injury remains a major cause of morbidity and mortality in paediatric intensive care units. Research over the past decade has altered our understanding of the pathophysiology of acute lung injury and the effects of mechanical ventilation on the lung. As a result, approaches to conventional mechanical ventilation of the injured lung are now largely centred around preservation of adequate gas exchange while protecting the lung from further ventilator-induced lung injury. Current techniques for accomplishing these goals include adjusting the ventilator based on the measurement and interpretation of pressure-volume curves, limitation of inspiratory tidal volumes, use of elevated levels of positive end-expiratory pressure, recruiting manoeuvres and prone positioning. The currently available data regarding the efficacy and appropriate use of these techniques are reviewed.
PMID: 15276135
ISSN: 1526-0542
CID: 3498322

Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression

Carpenter, Todd; Schomberg, Stacey; Steudel, Wolfgang; Ozimek, John; Colvin, Kelley; Stenmark, Kurt; Ivy, D Dunbar
Endothelin (ET) may contribute to pulmonary edema formation, particularly under hypoxic conditions, and decreases in ET-B receptor expression can lead to reduced ET clearance. ET increases vascular endothelial cell growth factor (VEGF) production in vitro, and VEGF overexpression in the lung causes pulmonary edema in vivo. We hypothesized that pulmonary vascular ET-B receptor deficiency leads to increased lung ET, that excess ET increases lung VEGF levels, promoting pulmonary edema formation, and that hypoxia exaggerates these effects. We studied these hypotheses in ET-B receptor-deficient rats. In normoxia, homozygous ET-B-deficient animals had significantly more lung vascular leak than heterozygous or control animals. Hypoxia increased vascular leak regardless of genotype, and hypoxic ET-B-deficient animals leaked more than hypoxic control animals. ET-B-deficient animals had higher lung ET levels in both normoxia and hypoxia. Lung HIF-1alpha and VEGF content was greater in the ET-B-deficient animals in both normoxia and hypoxia, and both HIF-1alpha and VEGF levels were reduced by ET-A receptor antagonism. Both ET-A receptor blockade and VEGF antagonism reduced vascular leak in hypoxic ET-B-deficient animals. We conclude that ET-B receptor-deficient animals display an exaggerated lung vascular protein leak in normoxia, that hypoxia exacerbates that leak, and that this effect is in part attributable to an ET-mediated increase in lung VEGF content.
PMID: 12919946
ISSN: 1524-4571
CID: 3498292